Erasca's Pan-RAS Drug Shows 57% Response in Pancreatic Cancer, Plans Phase 3 Trials
ERAS has more than doubled off its 52-week low of $1.33 on light trading volume (0.3× avg).
Summary
Updated Phase 1 AURORAS-1 data for ERAS-0015 shows a 57% unconfirmed overall response rate at 8 weeks (uORR8wk) in second-line or later KRAS G12X pancreatic ductal adenocarcinoma at the 32 mg recommended dose, with all responders still on treatment. The drug continues to be well-tolerated with 100% median relative dose intensity. First combination data with panitumumab in colorectal cancer showed no dose-limiting toxicities in the initial cohort. Erasca plans to start a potentially registration-enabling trial in lung cancer in H1 2027, a Phase 3 pancreatic cancer trial in 2027, and a second Phase 3 lung cancer trial by H1 2028. This follows the April 2026 preliminary data and the Merck collaboration announced in May, and comes despite ongoing legal challenges. The specific response rate and Phase 3 timelines materially de-risk the program and could position ERAS-0015 as a foundational therapy across multiple RAS-mutant tumors.
At the time of this announcement, ERAS was trading at $18.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.6B. The 52-week trading range was $1.33 to $24.28. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.